01:39 , Jun 29, 2019 |  BioCentury  |  Finance

Specialists and strong fundamentals must carry the sector in 3Q19

Heading into the third quarter, specialist biotech investors are in the driver’s seat, and their stances on whether to trim or spend in the down market are split. After recovering at the start of the...
01:42 , May 4, 2019 |  BioCentury  |  Product Development

How the amyloid hypothesis holds its grip

By now, two things are clear about the amyloid hypothesis of Alzheimer’s disease: one is that the amyloid peptide is somehow involved; the other is that it’s a terrible target. β amyloid has had an...
18:25 , Apr 19, 2019 |  BioCentury  |  Politics, Policy & Law

New White House policy could throttle FDA guidance-writing

A new Trump administration policy could slow the release of FDA guidance documents to a crawl, reducing transparency that product developers, patients and investors value. The policy is spelled out in an April 11 memo...
01:34 , Mar 23, 2019 |  BioCentury  |  Tools & Techniques

A frequentist and a Bayesian walk into a trial

In the stand-off between Bayesians and frequentists, the latter own the show for pivotal trials. But with non-profits leading the drive, Bayesians are poised to enter late-stage development via platform trials in cancer. The next...
00:00 , Mar 19, 2019 |  BioCentury  |  Regulation

Talk less, do more: Germline gene editing needs real plans, not just moratoria

We’ve moved on from sound and fury. We’re now just signifying nothing. The latest public proclamation on germline gene editing, couched in a call for a moratorium, is as much preaching to the choir as...
19:34 , Mar 1, 2019 |  BC Week In Review  |  Company News

CARB-X adds new members to increase number of funded antimicrobial research projects

Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) added six new organizations to its coalition, bringing its total membership to 10. With the new members, the non-profit aims to increase the number of early development antibacterial...
18:25 , Jun 13, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Cellular assays A method for measuring levels of lipolysis in abdominal white adipose tissue (WAT) could help predict the risk of diabetes. The method involves incubating abdominal WAT samples separately with isoprenaline, noradrenaline and...
00:36 , May 25, 2018 |  BC Innovations  |  Product R&D

Peptides step up

New screening platforms and synthetic approaches could finally solve some of the longstanding hurdles to turning antimicrobial peptides into therapeutic candidates to combat antibacterial resistance, overcoming their history of limited clinical efficacy, systemic toxicity and...
20:02 , May 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular; pulmonary

INDICATION: Myocardial infarction (MI); acute lung injury Patient sample and mouse studies suggest inhibiting CAMP could help treat MI and acute lung injury (ALI). In thrombus samples from MI patients, CAMP was highly expressed, and...
22:56 , Apr 20, 2018 |  Emerging Company Profile  |  Emerging Company Profile

Clear for Landos

Landos Biopharma Inc. is developing a first-in-class LANCL2 agonist designed to provide improved convenience, efficacy and safety over standard-of-care therapies for inflammatory bowel disease (IBD), including moderate to severe Crohn’s disease (CD) and ulcerative colitis...